COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:COLL • US19459J1043

46.75 USD
+0.47 (+1.02%)
At close: Feb 10, 2026
46.75 USD
0 (0%)
After Hours: 2/10/2026, 4:30:01 PM
Fundamental Rating

6

Taking everything into account, COLL scores 6 out of 10 in our fundamental rating. COLL was compared to 191 industry peers in the Pharmaceuticals industry. While COLL has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on COLL. This makes COLL very considerable for value investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year COLL was profitable.
  • In the past year COLL had a positive cash flow from operations.
  • Of the past 5 years COLL 4 years were profitable.
  • Each year in the past 5 years COLL had a positive operating cash flow.
COLL Yearly Net Income VS EBIT VS OCF VS FCFCOLL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 3.64%, COLL belongs to the top of the industry, outperforming 83.77% of the companies in the same industry.
  • COLL's Return On Equity of 21.27% is amongst the best of the industry. COLL outperforms 91.10% of its industry peers.
  • COLL's Return On Invested Capital of 9.10% is amongst the best of the industry. COLL outperforms 87.96% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for COLL is in line with the industry average of 12.66%.
Industry RankSector Rank
ROA 3.64%
ROE 21.27%
ROIC 9.1%
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
COLL Yearly ROA, ROE, ROICCOLL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

  • COLL's Profit Margin of 7.72% is amongst the best of the industry. COLL outperforms 82.20% of its industry peers.
  • COLL's Profit Margin has declined in the last couple of years.
  • COLL has a Operating Margin of 20.74%. This is amongst the best in the industry. COLL outperforms 89.01% of its industry peers.
  • COLL's Operating Margin has improved in the last couple of years.
  • COLL has a Gross Margin of 57.22%. This is in the better half of the industry: COLL outperforms 68.59% of its industry peers.
  • In the last couple of years the Gross Margin of COLL has grown nicely.
Industry RankSector Rank
OM 20.74%
PM (TTM) 7.72%
GM 57.22%
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
COLL Yearly Profit, Operating, Gross MarginsCOLL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

5

2. Health

2.1 Basic Checks

  • COLL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • COLL has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for COLL has been reduced compared to 5 years ago.
  • The debt/assets ratio for COLL has been reduced compared to a year ago.
COLL Yearly Shares OutstandingCOLL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
COLL Yearly Total Debt VS Total AssetsCOLL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.47, we must say that COLL is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.47, COLL perfoms like the industry average, outperforming 56.02% of the companies in the same industry.
  • COLL has a debt to FCF ratio of 2.79. This is a good value and a sign of high solvency as COLL would need 2.79 years to pay back of all of its debts.
  • COLL has a better Debt to FCF ratio (2.79) than 91.62% of its industry peers.
  • A Debt/Equity ratio of 2.71 is on the high side and indicates that COLL has dependencies on debt financing.
  • COLL's Debt to Equity ratio of 2.71 is on the low side compared to the rest of the industry. COLL is outperformed by 80.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF 2.79
Altman-Z 1.47
ROIC/WACC0.98
WACC9.3%
COLL Yearly LT Debt VS Equity VS FCFCOLL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • COLL has a Current Ratio of 1.36. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • COLL has a Current ratio of 1.36. This is in the lower half of the industry: COLL underperforms 73.82% of its industry peers.
  • COLL has a Quick Ratio of 1.27. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • COLL's Quick ratio of 1.27 is on the low side compared to the rest of the industry. COLL is outperformed by 69.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.27
COLL Yearly Current Assets VS Current LiabilitesCOLL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

5

3. Growth

3.1 Past

  • COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.73%, which is quite impressive.
  • The Earnings Per Share has been growing by 154.78% on average over the past years. This is a very strong growth
  • Looking at the last year, COLL shows a very strong growth in Revenue. The Revenue has grown by 26.34%.
  • The Revenue has been growing by 16.31% on average over the past years. This is quite good.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%

3.2 Future

  • Based on estimates for the next years, COLL will show a decrease in Earnings Per Share. The EPS will decrease by -1.58% on average per year.
  • Based on estimates for the next years, COLL will show a small growth in Revenue. The Revenue will grow by 3.62% on average per year.
EPS Next Y18.1%
EPS Next 2Y12.08%
EPS Next 3Y-0.6%
EPS Next 5Y-1.58%
Revenue Next Year24.13%
Revenue Next 2Y13.42%
Revenue Next 3Y4.47%
Revenue Next 5Y3.62%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
COLL Yearly Revenue VS EstimatesCOLL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
COLL Yearly EPS VS EstimatesCOLL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6 8

9

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 6.50, the valuation of COLL can be described as very cheap.
  • Based on the Price/Earnings ratio, COLL is valued cheaper than 94.76% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 28.03. COLL is valued rather cheaply when compared to this.
  • A Price/Forward Earnings ratio of 5.77 indicates a rather cheap valuation of COLL.
  • Based on the Price/Forward Earnings ratio, COLL is valued cheaper than 94.76% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.97, COLL is valued rather cheaply.
Industry RankSector Rank
PE 6.5
Fwd PE 5.77
COLL Price Earnings VS Forward Price EarningsCOLL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, COLL is valued cheaper than 98.43% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 96.86% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 5.11
EV/EBITDA 4.83
COLL Per share dataCOLL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • COLL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • COLL has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y12.08%
EPS Next 3Y-0.6%

0

5. Dividend

5.1 Amount

  • No dividends for COLL!.
Industry RankSector Rank
Dividend Yield 0%

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (2/10/2026, 4:30:01 PM)

After market: 46.75 0 (0%)

46.75

+0.47 (+1.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-19
Inst Owners120.33%
Inst Owner Change-0.06%
Ins Owners1.42%
Ins Owner Change-0.82%
Market Cap1.48B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.67
Price Target54.23 (16%)
Short Float %17.98%
Short Ratio10.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)9.25%
PT rev (3m)19.21%
EPS NQ rev (1m)-3.66%
EPS NQ rev (3m)3.56%
EPS NY rev (1m)-0.9%
EPS NY rev (3m)-16.04%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)5.33%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)4.02%
Valuation
Industry RankSector Rank
PE 6.5
Fwd PE 5.77
P/S 1.95
P/FCF 5.11
P/OCF 5.08
P/B 5.38
P/tB N/A
EV/EBITDA 4.83
EPS(TTM)7.19
EY15.38%
EPS(NY)8.1
Fwd EY17.33%
FCF(TTM)9.15
FCFY19.58%
OCF(TTM)9.2
OCFY19.69%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.36
PEG (5Y)N/A
Graham Number37.5
Profitability
Industry RankSector Rank
ROA 3.64%
ROE 21.27%
ROCE 13.6%
ROIC 9.1%
ROICexc 12.09%
ROICexgc N/A
OM 20.74%
PM (TTM) 7.72%
GM 57.22%
FCFM 38.21%
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF 2.79
Debt/EBITDA 1.94
Cap/Depr 0.72%
Cap/Sales 0.21%
Interest Coverage 2.17
Cash Conversion 75.92%
Profit Quality 495.01%
Current Ratio 1.36
Quick Ratio 1.27
Altman-Z 1.47
F-Score7
WACC9.3%
ROIC/WACC0.98
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y18.1%
EPS Next 2Y12.08%
EPS Next 3Y-0.6%
EPS Next 5Y-1.58%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year24.13%
Revenue Next 2Y13.42%
Revenue Next 3Y4.47%
Revenue Next 5Y3.62%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year157.27%
EBIT Next 3Y28.14%
EBIT Next 5Y18.85%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%

COLLEGIUM PHARMACEUTICAL INC / COLL FAQ

What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

ChartMill assigns a fundamental rating of 6 / 10 to COLL.


What is the valuation status for COLL stock?

ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.


What is the profitability of COLL stock?

COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.


Can you provide the financial health for COLL stock?

The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.